I watch more than 5,000 publicly traded companies with my tool, ranking companies by a number of fundamental and quantitative measures. And this week, I have seven feel-good pharma stocks to buy.
Here they are, in alphabetical order. Each one of these stocks gets an “A” or “B” according to my research, meaning it is a “strong buy” or “buy.”
Abbott Laboratories (NYSE:) discovers, develops, manufactures and sells a diversified line of health care products. Since the start of 2011, ABT stock is up 13%, compared to a 3% gain for the Dow Jones in the same time. ABT stock gets an “A” for return on equity in my Portfolio Grader tool. .
Bristol-Myers Squibb Co. (NYSE:) sells its pharmaceutical products mostly to wholesalers, retail pharmacies, hospitals and government entities. The big pharma stock is up more than 27% in just 12 months. BMY gets a “B” for earnings momentum, a “B” for the magnitude in which earnings projections have increased during the past month and an “A” for return on equity in my Portfolio Grader tool. .
Eli Lilly & Co. (NYSE:) manufactures its products in 19 countries and sells its products in more than 120. LLY has posted a return of 14% so far in 2011. LLY stock gets a “B” for cash flow and an “A” for return on equity in my Portfolio Grader tool. .
GlaxoSmithKline (NYSE:) is involved with vaccines, over-the-counter medicines and other health-related consumer products. GSK has posted a year-to-date gain of more than 13%. GSK stock gets an “A” for earnings momentum and an “A” for return on equity in my Portfolio Grader tool.
.
Johnson & Johnson (NYSE:) is a household name with more than 250 operating companies. JNJ stock has posted a modest gain of 1% for 2011, a little less than the broader markets. JNJ stock gets a “B” for earnings momentum and an “A” for return on equity in my Portfolio Grader tool. .
Pfizer (NYSE:) is a global pharmaceutical company that works with biopharmaceuticals and oncology products. PFE stock has gained 19% since the start of 2011. PFE stock gets an “A” for operating margin growth, an “A” for earnings growth, a “B” for its ability to exceed the consensus earnings estimates on Wall Street, a “B” for the magnitude in which earnings projections have increased during the past month, a “B” for cash flow and a “B” for return on equity in my Portfolio Grader tool. .
Sanofi (NYSE:) is known mostly for developing therapeutic solutions. Year-to-date, SNY stock has gained nearly 5%, compared to smaller gains by the broader markets. SNY stock gets an “A” for sales growth, a “B” for earnings momentum and a “B” for cash flow in my Portfolio Grader tool. .
Get more analysis of these picks and other publicly traded stocks with 抖阴最新版’s tool, a 100% free stock-rating tool that measures both quantitative buying pressure and eight fundamental factors.
